Arkolith/Insider Trading/CTMX/Form 4

Ogden Christopher

Chief Financial OfficerCytomX Therapeutics, Inc. (CTMX) · full profile →Form 4 · filed Sep 30, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 26, 2025Grant(A)39K—$039K
Sep 26, 2025Grant(A)78K—$078K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-25-000355) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML